AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02952222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients in Group DP will receive 0.5 mcg/kg Dexmedetomidine (DEX) administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of Bispectral Index (BIS) 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
Study NCT02952222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Group P)
Description: Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
Study NCT02952222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol (Group DP)
Description: Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
Study NCT03756038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
Study NCT03756038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
Study NCT05409339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 150 mg caffeine, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
Study NCT05409339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
Study NCT05409339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol, 3 times/day (wakeup + 45 min, +255 min, and +475 min)
Study NCT00413361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: versus hydroxychloroquine
Description: versus hydroxychloroquine
Study NCT00413361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: versus hydroxychloroquine
Description: versus hydroxychloroquine
Study NCT03868683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 1
Description: 30 g of glucose dissolved in 250 ml of water
Study NCT03868683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 2
Description: 30 g of glucose dissolved in 250 ml of water
Study NCT03868683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose reference 3
Description: 30 g of glucose dissolved in 250 ml of water
Study NCT03868683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: 30 g of Sucrose dissolved in 250 ml of water
Study NCT03868683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Bake beans in tomato sauce
Description: Bake beans in tomato sauce containing 14 g of sugar
Study NCT03868683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bake beans in tomato sauce, reduced sugar
Description: Bake beans in tomato sauce containing 12.2 g of sugar
Study NCT03868683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bake beans in tomato sauce, low GI
Description: Bake beans in tomato sauce containing 7.2 g of sugar
Study NCT02750462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography
Description: Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
Study NCT02750462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed/selective coronary angiography
Description: Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
Study NCT03047070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: IV Lidocaine infusion
Study NCT03047070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV normal saline infusion
Study NCT02981771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance activity program
Description: Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises
Study NCT02981771 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Strength activity program
Description: Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
Study NCT00637260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation on.
Description: The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
Study NCT00637260 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: motor cortex stimulation off
Description: The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
Study NCT00586573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine hydrochloride
Description: tablet, 5-20 mg, twice daily, by mouth, 12 weeks
Study NCT02469090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-130277
Description: Use to treat up to 5 OFF episodes per day
Study NCT02469090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04564586 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DPPFit
Description: Participants issued Fitbit Device and set up Fitbit App. They are then enrolled in the automated text messaging platform. Day 1 of the intervention begins the Monday after consent. All consented participants receive the full intervention.
Study NCT00085371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT04329195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1: discontinuation of RAS blocker therapy
Description: discontinuation of RAS blocker therapy
Study NCT04329195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2: continuation of RAS blocker therapy
Description: continuation of RAS blocker therapy
Study NCT02266693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT
Description: The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
Study NCT00525759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel
Description: 3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
Study NCT00525759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid
Description: 3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
Study NCT04507659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Morning: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets; Evening: 2\*50mg simulated tablets and 1\*75mg Jaktinib Hydrochloride Tablets.
Study NCT04507659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: Morning: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets; Evening: 1\*75mg simulated tablet, 2\*50mg Jaktinib Hydrochloride Tablets.
Study NCT04507659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Morning: 1\*75mg simulated tablet, 2\*50mg simulated tablets; Evening: 1\*75mg simulated tablet, 2\*50mg simulated tablets.
Study NCT00612443 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
Study NCT00612443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healing Touch
Description: Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
Study NCT01898182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetin, N6-furfuryladenine, 0.1%
Study NCT00117468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2011
Description: Administered vaginally from Day 14 to Day 31
Study NCT00117468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone 8% Vaginal Gel
Description: Administered vaginally from Cycle Day 14 to Day 31
Study NCT00005648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine with R115777
Description: R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
Study NCT00005648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine with Placebo
Description: Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
Study NCT01175109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib + LBH589
Description: Escalating doses of imatinib and LBH589 will be administered.
Study NCT01425203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)
Study NCT01425203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: boceprevir-matched placebo four 200-mg capsules PO TID.
Study NCT01425203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b
Description: peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
Study NCT01425203 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2b
Description: peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
Study NCT01425203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
Study NCT01425203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
Study NCT02419287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Study NCT01391507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9 % sodium chloride
Description: Monthly intravenous injection for 6 months
Study NCT01391507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR-1
Description: Monthly intravenous injection for 6 months
Study NCT01391507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for heart failure
Description: All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
Study NCT01391507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy for heart failure
Description: All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
Study NCT03700307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Description: Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
Study NCT01456676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib + LDE225
Description: Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
Study NCT03094871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACE-PC
Study NCT01780025 — intervention group
Intervention type: BEHAVIORAL
Intervention: Auditory evoked potentials and audiometry
Study NCT01780025 — intervention group
Intervention type: BEHAVIORAL
Intervention: Auditory evoked potentials
Description: Different protocols for audiometry and auditory evoked potentials
Study NCT04163068 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
Study NCT00283595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Growth Hormone
Description: Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
Study NCT00283595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Recombinant Human Growth Hormone
Description: Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
Study NCT00857727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
Study NCT00857727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given by a continuous infusion
Study NCT02961556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJG555
Description: Participants will receive 1 to 6 sachets daily per participants' age and conditions.
Study NCT04103437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental running test
Description: Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire
Study NCT04103437 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic and movement analysis of running
Description: Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters
Study NCT04103437 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Monthly follow-up questionnaire (12 months) about training habits and injuries
Study NCT00813423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study NCT00813423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00813423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00813423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT00845728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 µg
Description: Indacaterol 150 µg o.d. delivered via SDDPI
Study NCT00845728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium 18 µg o.d. delivered via handihaler®
Study NCT01716910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Combination of Lactobacillus acidophilus NCFM and cellobiose
Study NCT01716910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Combination of Lactobacillus acidophilus NCFM and cellobiose
Study NCT01803360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronate
Description: Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
Study NCT04418700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breath Stacking
Description: The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
Study NCT01338415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
Study NCT02206646 — intervention group
Intervention type: DRUG
Intervention: Metalyse
Study NCT01829256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist telehealth intervention
Description: A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
Study NCT00941876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Referral
Description: Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
Study NCT00798746 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone Questionnaire
Description: Ten questions regarding symptoms of reflux
Study NCT04451954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 1
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT04451954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 1 and adjuvant
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT04451954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 2
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT04451954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 2 and adjuvant
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular